XML 35 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets

12 Months Ended

May 27, 2012

Goodwill and Intangible Assets Disclosure [Text Block]

6. Intangible Assets

Changes in the carrying amount of goodwill for the fiscal years ended May 27, 2012, May 29, 2011 and May 30, 2010 by reportable segment, are as follows (in thousands):

	Food Products Technology		Technology Licensing			Hyaluronan-based Biomaterials		Total

Balance as of May 31, 2009	$	22,581	$	4,780		$	—	$	27,361
Goodwill acquired during the period		—		—			13,793		13,793
Balance as of May 30, 2010		22,581		4,780			13,793		41,154
Goodwill acquired/reclassified during the period		—		—			88		88
Goodwill impaired during the period		—		(4,780	)		—		(4,780	)
Balance as of May 29, 2011		22,581		—			13,881		36,462
Goodwill acquired during the period		13,158		—			—		13,158
Balance as of May 27, 2012	$	35,739	$	—		$	13,881	$	49,620

Information regarding Landec’s other intangible assets is as follows (in thousands):

	Trademarks & Trade names		Customer Relationships			Total
Balance as of May 31, 2009	$	8,228	$	—		$	8,228
Acquired during the period		4,200		3,700			7,900
Amortization expense		—		(26	)		(26	)
Balance as of May 30, 2010		12,428		3,674			16,102
Amortization expense		—		(308	)		(308	)
Balance as of May 29, 2011		12,428		3,366			15,794
Acquired during the period		36,000		7,500			43,500
Amortization expense		—		(309	)		(309	)
Balance as of May 27, 2012	$	48,428	$	10,557		$	58,985

Accumulated amortization as of May 27, 2012, May 29, 2011 and May 30, 2010 was $4.1 million, $3.8 million and $3.4 million, respectively. Accumulated impairment losses through May 27, 2012 were $4.8 million. Lifecore’s customer relationships amount of $3.7 million is being amortized over 12 years and GreenLine’s customer relationships amount of $7.5 million is being amortized over 13 years. The amortization expense for the next five fiscal years will be $885,000 per year.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details